Co-Authors
This is a "connection" page, showing publications co-authored by Roberto Caporali and Sara Monti.
Connection Strength
2.563
-
Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology (Oxford). 2018 10 01; 57(57 Suppl 7):vii54-vii58.
Score: 0.788
-
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. Mod Rheumatol. 2018 May; 28(3):542-549.
Score: 0.732
-
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017 Apr; 36(4):753-761.
Score: 0.699
-
20 years of experience with tumour necrosis factor inhibitors: what have we learned? Rheumatology (Oxford). 2018 10 01; 57(57 Suppl 7):vii5-vii10.
Score: 0.197
-
Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data? Arthritis Rheumatol. 2020 10; 72(10):1600-1606.
Score: 0.056
-
How I treat idiopathic patients with inflammatory myopathies in the clinical practice. Autoimmun Rev. 2017 Oct; 16(10):999-1007.
Score: 0.045
-
The role of ultrasound in the diagnosis and follow-up of large-vessel vasculitis: an update. Clin Exp Rheumatol. 2017 Mar-Apr; 35 Suppl 103(1):194-198.
Score: 0.044